healthi
male
volunt
took
part
clinic
trial
volunt
took
chloroquin
chemoprophylaxi
receiv
three
intraderm
dose
fourweek
interv
asept
purifi
plasmodium
falciparum
sporozoit
induc
protect
immun
malaria
fiftynin
day
last
administr
sporozoit
day
last
dose
chloroquin
volunt
underw
control
human
malaria
infect
chmi
bite
five
p
falciparuminfect
mosquito
eleven
day
postchmi
thick
blood
smear
posit
p
blood
treatment
initi
atovaquoneproguanil
second
day
treatment
day
postchmi
troponin
marker
cardiac
tissu
damag
began
rise
normal
reach
maximum
ngl
upper
rang
normal
ngl
day
postchmi
volunt
minut
episod
retrostern
chest
pain
heavi
feel
left
arm
day
postchmi
ecg
time
reveal
minor
repolar
disturb
cardiac
mri
demonstr
focal
area
subepicardi
midwal
delay
enhanc
left
ventricl
oedema
hypokinesia
diagnosi
myocard
made
troponin
level
normal
within
day
volunt
recov
without
clinic
sequela
followup
cardiac
mri
almost
five
month
show
normal
function
ventricl
disappear
oedema
delay
enhanc
subepicardi
midwal
region
decreas
still
present
except
throat
swab
posit
rhinoviru
day
postchmi
test
potenti
aetiolog
myocard
posit
number
possibl
aetiolog
factor
may
explain
contribut
case
myocard
includ
p
falciparum
infect
ii
rhinoviru
infect
iii
unidentifi
pathogen
iv
hyperimmun
volunt
receiv
six
travel
vaccin
last
immun
chmi
v
atovaquoneproguanil
treatment
vi
combin
factor
definit
aetiolog
pathophysiolog
mechan
myocard
establish
control
human
malaria
infect
chmi
use
nearli
centuri
treatment
neurosyphili
assess
intervent
like
drug
vaccin
treat
prevent
malaria
howev
modern
era
chmi
began
mid
laboratori
rear
anophel
sp
mosquito
infect
feed
cultur
plasmodium
falciparuminfect
blood
past
three
decad
chmi
shown
safe
welltoler
use
evalu
potenti
new
antimalari
drug
vaccin
exposur
bite
laboratoryrear
mosquito
infect
p
falciparum
sporozoit
pfspz
clinic
symptom
sign
malaria
gener
mild
moder
last
day
commonli
report
symptom
headach
fever
myalgia
fatigu
common
laboratori
abnorm
includ
clinic
insignific
thrombocytopaenia
leukopaenia
subject
undergo
chmi
close
monitor
immedi
treat
antimalari
upon
detect
parasitaemia
due
frequent
intens
clinic
monitor
initi
treatment
almost
alway
occur
parasit
densiti
less
often
densiti
lower
parasit
densiti
associ
caus
sever
malaria
immun
volunt
take
chloroquin
chemoprophylaxi
whole
pfspz
administ
mosquito
bite
result
complet
longlast
protect
chmi
p
falciparuminfect
mosquito
immun
approach
call
chemoprophylaxi
sporozoit
cp
sinc
cp
depend
inocul
pfspz
mosquito
bite
implement
vaccin
recent
subject
infect
needl
syring
inocul
asept
purifi
cryopreserv
pfspz
product
call
pfspz
challeng
subsequ
clinic
trial
initi
volunt
take
chloroquin
chemoprophylaxi
inject
intraderm
id
fourweek
interv
pfspz
challeng
approach
call
pfspzcvac
approach
pfspz
chemoprophylaxi
vaccin
underw
chmi
probabl
case
acut
myocard
describ
volunt
taken
chloroquin
chemoprophylaxi
inocul
three
time
fourweek
interv
pfspz
challeng
receiv
six
travelrel
routin
vaccin
immun
procedur
chmi
bite
five
pfspzinfect
mosquito
week
last
dose
pfspz
challeng
week
last
dose
chloroquin
sore
throat
day
chmi
develop
p
falciparum
parasitaemia
treat
day
chmi
asymptomat
initi
elev
troponin
level
day
chmi
healthi
male
volunt
enrol
doubl
blind
random
control
trial
assess
safeti
toler
protect
efficaci
chmi
pfspzinfect
mosquito
intraderm
administr
asept
purifi
cryopreserv
pfspz
pfspz
challeng
volunt
take
weekli
mg
chloroquin
prophylaxi
pfspzcvac
approach
medic
histori
unremark
smoke
use
illicit
drug
mother
histori
hypertens
patern
grandfath
histori
heart
valv
defect
possibl
myocardi
infarct
age
inclus
physic
examin
within
normal
limit
blood
pressur
mmhg
heart
rate
beat
per
minut
bodi
mass
index
kgm
electrocardiographi
ecg
show
commonli
seen
normal
variant
incomplet
right
bundl
branch
block
see
addit
file
standard
laboratori
test
inclus
normal
see
tabl
octob
decemb
receiv
three
intraderm
inject
fourweek
interv
pfspz
pfspz
challeng
dilut
phosphat
buffer
salin
human
serum
albumin
day
day
first
immun
report
sore
throat
symptom
common
cold
ie
stuffi
nose
cough
mild
chill
hour
complaint
report
second
third
immun
clinic
signific
laboratori
abnorm
found
immun
period
fiftynin
day
third
last
immun
day
last
dose
chloroquin
underw
chmi
bite
five
p
falciparuminfect
mosquito
day
postchmi
complain
sore
throat
day
postchmi
thick
blood
smear
becam
posit
p
blood
infect
erythrocyt
standard
treatment
mg
atovaquon
plu
mg
proguanil
daili
three
day
initi
retrospect
assess
parasitaemia
quantit
polymeras
chain
reaction
qpcr
reveal
parasitesml
infect
erythrocyt
day
thick
smear
posit
day
complain
minor
chill
headach
hour
highest
record
sublingu
temperatur
platelet
lymphocyt
count
decreas
l
normal
rang
l
l
normal
rang
l
respect
often
seen
malaria
posit
individu
level
troponin
highli
sensit
assay
normal
ie
ngl
upper
limit
normal
ngl
troponin
specif
marker
myocardi
tissu
damag
second
day
malaron
treatment
day
postchmi
troponin
level
elev
ngl
increas
ngl
even
abnorm
seen
ecg
apart
mild
headach
fatigu
follow
day
day
postchmi
volunt
asymptomat
troponin
ngl
morn
ngl
afternoon
blood
pressur
mmhg
ecg
reveal
mild
repolar
disturb
diffus
sttsegment
elev
suggest
pericard
see
addit
file
echocardiogram
show
mild
hypokinesia
inferior
wall
slightli
diminish
global
left
ventricl
lv
function
calcul
lv
eject
fraction
normal
rang
young
man
malaron
treatment
complet
qpcr
p
falciparum
neg
day
postchmi
although
subject
cardiac
chest
symptom
hospit
cardiolog
depart
accord
safeti
protocol
telemetr
ecgmonitor
followup
troponin
level
night
experienc
retrostern
pain
heavi
feel
left
arm
approxim
minut
sublingu
nitroglycerin
spray
administ
chest
pain
disappear
immedi
minut
administr
nitroglycerin
pain
relat
breath
concomit
complaint
sign
dyspnoea
pyrosi
ructu
subject
never
anoth
episod
chest
pain
cardiac
mri
sever
hour
later
day
postchmi
show
slightli
increas
signal
intens
basaland
midinferolater
partli
midanterolater
myocardi
segment
match
minor
oedema
see
figur
ii
focal
area
subepicardi
midwal
delay
enhanc
basaland
midinferior
basaland
midinferolater
segment
administr
gadolinium
contrast
see
figur
c
iii
hypokinesia
basaland
midinferior
mild
hypokinesia
basaland
midinferolater
find
interpret
indic
myocard
treatment
start
day
postchmi
betablock
metoprolol
mg
twice
daili
reduc
chanc
cardiac
arrhythmia
accord
treatment
guidelin
patient
reduc
lvfunction
troponin
level
continu
rise
peak
ngl
day
chmi
follow
day
troponin
decreas
eventu
return
normal
day
initi
increas
correspond
day
postchmi
creatin
kinas
ck
show
similar
pattern
rise
fall
return
normal
day
postchmi
biochem
marker
cardiac
wall
stress
ntermin
prohormon
brain
natriuret
peptid
ntprobnp
slightli
elev
day
postchmi
normal
day
postchmi
see
tabl
limit
rise
fall
aspart
aminotransferas
ast
lactat
dehydrogenas
ldh
found
nonspecif
marker
increas
coagul
inflamm
ddimer
remain
within
normal
rang
minim
elev
first
day
thick
smear
posit
similarli
inflammatori
acutephas
protein
creactiv
protein
crp
slightli
elev
day
chmi
see
tabl
four
day
admiss
day
postchmi
ecg
echocardiogram
normal
see
addit
file
calcul
lv
eject
fraction
normal
rang
volunt
discharg
apart
singl
short
episod
chest
pain
longer
period
fatigu
occasion
mild
headach
shortli
hospit
complaint
report
fatigu
diminish
tabl
laboratori
find
haematolog
biochemistri
test
normal
rang
inclus
c
c
c
c
c
c
c
c
c
ddimer
ngml
clinic
laboratori
find
inclus
day
start
trial
day
thick
smear
posit
c
day
chmi
subsequ
day
chmi
halv
dose
metoprolol
mg
daili
day
postchmi
remain
mild
fatigu
complet
disappear
three
week
later
day
postchmi
discharg
volunt
complain
occasion
mild
headach
anymor
volunt
receiv
pretravel
vaccin
diphtheria
tetanu
polio
typhu
hepat
hepat
b
day
third
inject
pfspz
challeng
day
chmi
booster
vaccin
hepat
b
day
third
inject
day
chmi
polymeras
chain
reaction
pcr
analys
throat
smear
faec
whole
blood
carri
virus
bacteria
known
caus
myocard
see
tabl
throat
smear
pcr
posit
rhinoviru
pcr
result
neg
tabl
virolog
bacteriolog
parasitolog
serolog
perform
sampl
obtain
three
week
inclus
day
postchmi
see
tabl
repeat
test
day
later
day
postchmi
day
first
elev
troponin
serolog
result
neg
furthermor
urin
toxicolog
screen
amphetaminederiv
cocain
cannabinoid
diazepam
methadon
tramadol
hydrochlorid
opiat
neg
day
chmi
almost
five
month
first
mri
repeat
cardiac
mri
demonstr
good
function
left
ventricl
calcul
lv
eject
fraction
persist
mild
hypokinesia
midinferior
midinferolater
segment
left
ventricl
oedema
disappear
complet
see
figur
concomitantli
delay
enhanc
decreas
mostli
basalinferolater
segment
see
figur
c
howev
patchi
midwal
subepicardi
delay
enhanc
still
present
four
myocardi
segment
ie
basalinferolater
midinferolater
basalinferior
midinferior
segment
followup
ecg
show
abnorm
except
minim
widen
qr
complex
compar
pretrial
ecg
persist
incomplet
right
bundl
branch
block
see
addit
file
addit
ecg
cardiac
stress
test
show
sttsegment
chang
rhythm
abnorm
chang
respect
pretrial
ecg
cardiac
stress
test
use
cycl
protocol
start
watt
increas
step
watt
per
minut
reach
maxim
achiev
power
watt
ie
expect
age
group
gender
adequ
increas
blood
pressur
heart
rate
heart
rate
pressur
product
mmhgmin
normal
mmhgmin
metoprolol
mg
daili
stop
volunt
remain
without
complaint
good
condit
clinic
suspect
acut
myocard
typic
mri
characterist
report
healthi
volunt
particip
pfspzcvac
approach
phase
clinic
trial
first
myocard
manifest
occur
day
last
dose
pfspz
challeng
day
last
dose
chloroquin
day
receiv
pretravel
vaccin
day
chmi
p
falciparuminfect
mosquito
bite
three
day
onset
sore
throat
one
day
diagnosi
p
falciparum
malaria
initi
treatment
malaria
retrostern
chest
pain
kinet
increas
troponin
plasma
concentr
ecg
echocardiogram
find
mri
find
consist
guidelin
intern
consensu
group
mr
diagnosi
myocard
support
diagnosi
acut
myocard
moreov
improv
myocardi
function
disappear
oedema
reduc
delay
enhanc
almost
five
month
correspond
natur
cours
acut
myocard
residu
delay
enhanc
consist
contrast
retent
fibrou
tissu
addit
bnp
ntprobnp
temporarili
elev
elev
also
found
patient
myocard
associ
reduc
left
ventricular
function
occurr
cardiac
event
relat
time
residu
parasitaemia
cur
malaron
treatment
postchmi
might
suggest
causal
relationship
case
malaria
concomit
myocard
report
literatur
albeit
restrict
patient
sever
fatal
infect
p
falciparum
plasmodium
vivax
malaria
literatur
myocard
never
report
patient
uncompl
p
falciparum
malaria
even
patient
present
p
falciparum
parasit
densiti
time
higher
parasit
densiti
volunt
addit
troponin
plasma
concentr
never
shown
elev
background
unselect
group
volunt
daili
measur
chmi
use
highli
sensit
assay
person
commun
rw
sauerwein
radboud
univers
medic
center
netherland
consist
find
troponin
rare
elev
assess
retrospect
patient
uncompl
p
falciparum
malaria
contrast
african
children
sever
andor
fatal
p
falciparum
malaria
exhibit
high
high
level
circul
cardiac
protein
indic
myocardi
injuri
impair
left
ventricular
function
previous
cardiac
seriou
advers
event
report
femal
volunt
particip
phase
clinic
trial
immun
subunit
recombin
protein
malaria
vaccin
underw
chmi
mosquito
bite
develop
malaria
treat
artemetherlumefantrin
diagnos
acut
coronari
syndrom
two
day
complet
treatment
myocard
consid
possibl
altern
diagnosi
apart
one
confirm
myocardi
infarct
male
volunt
increas
cardiovascular
risk
underw
chmi
develop
parasitaemia
report
cardiac
complic
approxim
subject
undergon
chmi
sinc
report
chulay
et
al
current
case
cardiac
event
occur
three
day
subject
receiv
cur
malaron
treatment
p
falciparum
malaria
previou
data
indic
antimalari
treatment
atovaquoneproguanil
metabolit
cycloguanil
caus
myocard
signific
cardiovascular
toxic
furthermor
product
monograph
malaron
mention
cardiotox
myocard
palpit
tachycardia
common
caus
acut
myocard
healthi
young
individu
viral
infect
numer
infecti
pathogen
caus
acut
myocard
enterovirida
includ
coxsacki
b
respons
case
past
recent
virus
includ
adenoviru
parvoviru
hepat
c
also
emerg
import
cardiotrop
pathogen
current
volunt
diagnost
test
common
infecti
caus
myocard
neg
see
tabl
howev
neg
convalesc
antibodi
titer
exclud
postinfecti
myocard
furthermor
throat
swab
taken
two
day
initi
increas
troponin
contain
rhinoviru
rhinoviru
occasion
associ
myocard
noteworthi
rhinoviru
often
detect
pcr
asymptomat
subject
causal
infer
symptomat
patient
therefor
made
caution
pathogenesi
myocard
due
direct
infect
myocardium
replic
pathogen
host
specif
immunolog
respons
infect
nonspecif
immunolog
respons
suscept
individu
could
trigger
case
malaria
infect
case
one
would
expect
find
marker
inflamm
elev
howev
marker
nonspecif
inflamm
haemolysi
ddimer
crp
ldh
normal
slightli
elev
troponin
level
highest
see
tabl
nonetheless
possibl
overal
hyperreact
induc
six
standard
vaccin
ie
diphtheria
poliomyel
tetanu
parenter
typhoid
fever
hepat
hepat
b
volunt
receiv
immun
period
chmi
subsequ
chmi
could
gener
hypersensit
myocard
postvaccin
myocard
rare
report
administ
vaccin
usual
manifest
fever
andor
nonspecif
inflammatori
symptom
within
sever
day
hyperimmun
occur
volunt
nonetheless
explan
rule
system
allerg
reaction
local
advers
event
occur
volunt
receiv
three
intraderm
id
inject
pfspz
pfspz
challeng
moreov
system
allerg
reaction
among
subject
receiv
singl
dose
pfspz
challeng
id
n
intramuscular
im
n
intraven
iv
n
rout
order
studi
safeti
infect
pfspz
challeng
person
commun
sl
hoffman
sanaria
inc
usa
among
volunt
receiv
six
dose
radiationattenu
pfspz
pfspz
vaccin
id
n
subcutan
sc
n
iv
n
thu
seem
extrem
unlik
parenter
administ
pfspz
phosphat
buffer
salin
human
serum
albumin
pfspz
administ
contribut
myocard
contain
immunolog
sensit
agent
myocard
may
also
trigger
toxin
alcohol
cocain
chemotherapeut
antibiot
metabol
abnorm
factor
howev
volunt
deni
excess
use
alcohol
urin
drug
test
cocain
amphetamin
cannabinoid
neg
make
factor
unlik
explan
alcohol
intak
quantifi
followup
visit
chmi
volunt
repetit
instruct
restrict
alcohol
intak
sinc
urin
drug
test
perform
five
day
first
rise
troponin
detect
metabolit
cocain
amphetamin
singl
use
quit
limit
time
could
miss
conclus
differ
possibl
caus
myocard
definit
caus
case
establish
also
possibl
combin
abovediscuss
potenti
aetiolog
factor
could
contribut
develop
case
acut
myocard
inform
consent
public
case
report
obtain
volunt
particip
clinic
trial
